Yes, and also from the Chairman's Blog under MANF
Post# of 30028
Quote:
The Company is also continuing to move forward with other initiatives on the MANF front with Dr. Larry Schwartz at the University of Massachusetts, including the further evaluation of MANF as a treatment for the orphan indication antibiotic-induced ototoxicity, as well as other undisclosed possibilities. - See more at: http://www.thechairmansblog.com/amarantus-bio...sh4Bv.dpuf
It seems as though he is planning on priming the AMBS pipeline.
GLTA,
GO AMBS